Free shipping on all orders over $ 500

Oprozomib

Cat. No. M2150

All AbMole products are for research use only, cannot be used for human consumption.

Oprozomib Structure
Synonym:

ONX 0912, PR-047

Size Price Availability Quantity
10mg USD 170  USD170 In stock
50mg USD 580  USD580 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Oprozomib (ONX 0912, PR-047) is an orally bioavailable and selective proteasome inhibitor. Oprozomib (ONX 0912) selectively inhibited CT-L activity of both the constitutive proteasome (beta5) and immunoproteasome (LMP7) and demonstrated an absolute bioavailability of up to 39% in rodents and dogs. Oprozomib inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies. The anti-MM activity of Oprozomib (ONX 0912) is associated with activation of caspase-8, caspase-9, caspase-3, and poly(ADP) ribose polymerase, as well as inhibition of migration of MM cells and angiogenesis. Oprozomib significantly reduced tumor progression and prolonged survival in animal tumor model studies. Immununostaining of MM tumors from ONX 0912-treated mice showed growth inhibition, apoptosis, and a decrease in associated angiogenesis. Finally, Oprozomib (ONX 0912) enhances anti-MM activity of bortezomib, lenalidomide dexamethasone, or pan-histone deacetylase inhibitor.

Chemical Information
Molecular Weight 532.61
Formula C25H32N4O7S
CAS Number 935888-69-0
Solubility (25°C) DMSO 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Chauhan D, et al. Blood. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

[2] Zhou HJ, et al. J Med Chem. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

Related Proteasome Products
Proteasome inhibitor IX

Proteasome inhibitor IX (PS-IX; AM114) is a Chalcone derivative and a chymotrypsin-like activity of the 20S proteasome inhibitor with an IC50 value of ~1 μM.

NIC-0102

NIC-0102 is an orally potent proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammasome activation.NIC-0102 showed potent anti-inflammatory effects in vivo in a DSS-induced ulcerative colitis model. In addition, NIC-0102 inhibited the production of pro-IL-1β.

Ac-WLA-AMC

Ac-WLA-AMC is a specific 20S constitutive proteasome β5 fluorogenic substrate.

Ac-Nle-Pro-Nle-Asp-AMC

Ac-Nle-Pro-Nle-Asp-AMC is a specific substrate for 26S proteasome.

PR-39

PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Oprozomib, ONX 0912, PR-047 supplier, Proteasome, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.